Kyle Carver - Nov 7, 2025 Form 4 Insider Report for Evommune, Inc. (EVMN)

Role
Chief Financial Officer
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol
EVMN
Transactions as of
Nov 7, 2025
Transactions value $
$0
Form type
4
Date filed
11/12/2025, 04:16 PM
Previous filing
Nov 5, 2025
Next filing
Dec 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Carver Kyle Chief Financial Officer C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO /s/ Gregory S. Moss, Attorney-in-Fact 2025-11-12 0001757072

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVMN Common Stock Conversion of derivative security +3.18K +4.37% 75.8K Nov 7, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVMN Series B Preferred Stock Conversion of derivative security -25K -100% 0 Nov 7, 2025 Common Stock 3.18K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.